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FOREWORD 
 
Despite being a well known and widely used word, the precise definition of “neoplasia” 
is still debatable. One of the most cited definitions of neoplasia belongs to Rupert A. Willis in his 
famous book “The spread of tumours in the human body” published in 19521: “A neoplasm is an 
abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of the 
normal tissues and persists in the same excessive manner after cessation of the stimuli which 
evoked the change.” In the last years, many authors2 realize that neoplasia, besides being literally 
the formation of something new, through the proliferation or increase survival of the neoplastic 
cells, is instead, a complex tissue made of several different cell types that establish interactions 
with each other. Such different cell types include not only neoplastic cells, but also cells of the 
microenvironment, like cancer associated-fibroblasts3-5, immune cells6, 7, pericytes 8, 9 or even 
bone marrow-derived cells10, 11, among others. Far from being considered static elements, the 
cells of the microenvironment can be recruited to the bulk of the neoplasia and promote initiation 
and evolution of this tissue – in other words, normal cells with normal genotype can increase or 
decrease the malignant behavior of the neoplastic cells. 
As a complex tissue that does not respect the boundaries of normal tissue architecture, 
neoplasia is also regulated by non-cellular elements of the microenvironment which carry 
autocrine and paracrine signals. These signals that control normal and neoplastic tissue 
architecture imbalance (cell number and position) are transmitted from one cell to the other, 
through stroma, in a very tightly regulated fashion, in which time is a very important factor. The 
effects of the non-cellular elements and their temporal variation are very difficult to access 
experimentally. Nevertheless, the mechanisms involved in the maintenance of architecturally 
complex tissues should be searched in order to obtain a more profound knowledge on neoplasia 
behavior.2, 12, 13 
Accordingly, the biology of neoplasia can only be fully understood through the study of 
the cross-talk between neoplastic cells and their microenvironment rather than keep the study 
focus on a strict group of neoplastic cells that are known to be extremely heterogeneous.14 
Recently, the characterization of the genomes of neoplastic cells microdissected from different 
areas of the same tumor has revealed intratumoral genetic heterogeneity15, 16, which has relevant 
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implications in cancer therapy as well as in the establishment of cancer study strategies. It is no 
longer sufficient to understand neoplasia just by studying a single neoplastic cell genome. 
The ability to invade and to disseminate by the neoplastic cells, through the activation of 
a regulatory program, known as epithelial-mesenchymal transition (EMT) 17-19, epitomizes the 
product of the epigenetic induced heterogeneity. The EMT induced by epigenetic alterations is 
reflected by the loss of adherens junctions, the conversion to a spindly morphology, expression 
of matrix-degrading enzymes and increased cell motility.20-22 These epigenetic mechanisms may 
not only be important in neoplastic cells but also in the cellular and non-cellular elements of the 
microenvironment.23 
Using the colorectal cancer (CRC) as a model, we collected from the Department of 
Pathology of Portuguese Oncology Institute-Porto a series of morphologically characterized 
cases of colorectal adenocarcinoma with long term follow-up and studied the expression of 
different epigenetic marks. In this study, in a attempt to shed some light in CRC carcinogenesis, 
the protein expression of histone modifying enzymes and histone marks were assessed by 
immunohistochemical analysis and searched for the association between the expression of these 
proteins and the clinicopathological features of the cases, as well as with the patient´s outcome 
and therapeutic response. 
This study allowed the identification of new biomarkers that might be used in clinical 
practice, at a low cost, and gives rise to new directions of research in CRC carcinogenesis. 
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LIST OF ABBREVIATIONS 
APC – adenomatous polyposis coli protein 
ASH1L - histone-lysine N-methyltransferase ASH1L (absent small and homeotic disks protein 1 
homolog) 
BIM - Bcl-2-like protein 11 
BMP – bone morphogenetic protein 
BRAF – serine/threonine-protein kinase B-raf (v-Raf murine sarcoma viral oncogene homolog 
B1) 
CI – confidence interval 
CIN – chromosome instability 
c-MYC – Myc proto-oncogene protein (v-myc myelocytomatosis viral oncogene homolog) 
CpG – cytosine guanine (linear dinucleotide) 
CRC – colorectal cancer 
DAB – 3,3´-diaminobenzidine 
DCC – Netrin receptor DCC (deleted in colorectal cancer) 
DNA – deoxyribonucleic acid 
DNMT – DNA methyltransferase 
EDTA – ethylenediamine tetraacetic acid 
EHMT1 – histone-lysine N-methyltransferase EHMT1 (euchromatic histone-lysine N-
methyltransferase 1), also known as G9a-like protein 1 (GLP1) 
EHMT2 - histone-lysine N-methyltransferase EHMT2 (euchromatic histone-lysine N-
methyltransferase 2), also known as protein G9a 
EMT – epithelial-to-mesenchymal transition 
EZH2 – Histone-lysine N-methyltransferase EZH2 (Enhancer of Zeste Homolog 2) 
E2F - transcription factor E2F 
FAP – familial adenomatous polyposis 
FOBT – fecal occult blood testing 
FOLFIRI – fluorouracil + leucovorine + irinotecan 
FOLFOX – fluorouracil + leucovorine + oxaliplatin 
5-FU – fluorouracil 
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HDAC – histone deacetylase 
HDAC1 - histone deacetylase 1 
H-score – modified Histo-score 
H2AK5ac – acetylation of lysines 5 in histone H2A 
H2O2 – hydrogen peroxide 
H3K4 – lysine 4 in histone H3 
H3K4me2 – dimethylation of lysines 4 in histone H3 
H3K4me3 – trimethylation of lysine 4 in histone H3 
H3K9 – lysine 9 in histone H3 
H3K9ac – acetylation of lysines 9 in histone H3 
H3K9me3 – trimethylation of lysine 9 in histone H3 
H3K18ac – acetylation of lysines 18 in histone H3 
H3K27 – lysine 27 in histone H3 
H3K27me3 – trimethylation of lysine 27 in histone H3 
H3K36 – lysine 36 in histone H3 
H3K79 – lysine 79 in histone H3 
H4K12ac – acetylation of lysines 12 in histone H4 
H4K20 – lysine 20 in histone H4 
H4K20me3 – trimethylation of lysines 20 in histone H4 
H4R3me2 – dimethylation of arginine 3 in in histone H4 
IHC – immunohistochemistry 
JARID1 - lysine-specific demethylase 5A (Jumonji/ARID domain-containing protein 1A) 
JMJD1A – lysine-specific demethylase 3A (Jumonji domain-containing protein 1A) 
JMJD1B – lysine-specific demethylase 3B (Jumonji domain-containing protein 1B) 
JMJD2A – lysine-specific demethylase 4A (Jumonji domain-containing protein 2A) 
JMJD2B – lysine-specific demethylase 4B (Jumonji domain-containing protein 2B) 
JMJD2C – lysine-specific demethylase 4C (Jumonji domain-containing protein 2C) 
JMJD2D - lysine-specific demethylase 4D (Jumonji domain-containing protein 2D) 
JMJD3 - lysine-specific demethylase 6B (Jumonji domain-containing protein 3) 
KDM6A - lysine-specific demethylase 6A 
KDM6B - lysine-specific demethylase 6B, also known as JMJD3 
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KRAS – GTPase KRas (v-ki-ras2 Kirsten rat sarcoma viral oncogene homolog) 
LSD1 – lysine-specific histone demethylase 1A 
MBD – methyl-CpG-binding domain protein 
MGMT – Methylated-DNA-protein-cysteine methyltransferase (6-0-methylguanine-DNA 
methyltransferase) 
miRNA – microRNA 
MLH1 – DNA mismatch repair protein Mlh1 (MutL protein homolog 1) 
MLL - histone-lysine N-methyltransferase MLL (Myeloid/lymphoid or mixed-lineage leukemia) 
MMP – matrix metalloproteinase 
MMP-9 - matrix metalloproteinase-9 (gelatinase B, type IV collagenase) 
MMR – mismatch repair 
mRNA – messenger ribonucleic acid 
MSI – microsatellite instability 
NC – not computed 
NS – not significant 
OS – overall survival 
PBS – phosphate buffered saline 
PcG – polycomb group 
PI3K – phosphatidylinositol 3-kinase 
PRC – polycomb-repressor complex 
PRDM2 – PR domain zinc finger protein 2 (retinoblastoma protein-interacting zinc finger 
protein), also known as RIZ 
p21 - cyclin-dependent kinase inhibitor 1 
RAS – rat sarcoma viral oncogene 
RASSF1A - Ras association domain-containing protein 1 
RNA – ribonucleic acid 
RTK – receptor tyrosine kinase 
RUNX3 - Runt-related transcription factor 3 
SET1A - histone-lysine N-methyltransferase SETD1A (SET domain-containing protein 1A) 
SET1B - histone-lysine N-methyltransferase SETD1B (SET domain-containing protein 1B) 
SETDB1 – histone-lysine N-methyltransferase SETDB1 (SET domain bifurcated 1) 
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SETDB2 – histone-lysine N-methyltransferase SETDB2 (SET domain bifurcated 2) 
SMAD4 – mothers against decapentaplegic homolog 4 
SMYD2 – N-lysine methyltransferase SMYD2 (SET and MYND domain-containing protein 2) 
SMYD3 – SET and MYND domain-containing protein 3 (zinc finger MYND domain-containing 
protein 1) 
SNP – single-nucleotide polymorphism 
SPSS – Statistical Package for the Social Sciences 
Suv39 – histone-lysine N-methyltransferase Su(var)3-9 (protein suppressor of variegation 3-9) 
SUV39H1 – histone-lysine N-methyltransferase SUV39H1 (suppressor of variegation 3-9 
homolog 1) 
SUV39H2 – histone-lysine N-methyltransferase SUV39H2 (suppressor of variegation 3-9 
homolog 2) 
TARBP2 – RISC-loading complex subunit TARBP2 (Trans-activation-responsive RNA-binding 
protein) 
TBST – Tris-buffered solution with 0.05% Tween 20 solution 
TCF4 – transcription factor 4 
TGF – transforming growth factor 
TGFb-1 - transforming growth factor beta-1 
TP53 – cellular tumor antigen p53 
VEGFR1 - vascular endothelial growth factor receptor 1 
WNT – wingless/integrated 
WNT10B - protein Wnt-10b 
χ2 – Pearson´s chi-squared test 
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ABSTRACT 
In Portugal, colorectal cancer (CRC) is the most incident cancer and the second main 
cause of cancer-related death. The clinical outcome of CRC can vary significantly, hence, it is 
important to subclassify the patients with CRC in order to predict the prognosis and treatment 
response. Several studies have shown that colorectal carcinogenesis involves not only genetic 
alterations but also epigenetic modifications. Despite several different types of histone post-
translational modifications, only a few have been relatively well studied, including histone 
acetylation and methylation. These modifications are due to the activity of several enzymes, such 
as histone methyltransferases and histone demethylases, and alterations in their expression levels 
have been found in several neoplasms. In addition, alterations in the pattern of histone 
modifications, specifically performed by the above mentioned chromatin-modifying enzymes, 
have been also associated with several types of tumors and their outcome. 
The overall objective of this study was to characterize the expression of four histone 
modifying enzymes, including the histone methyltransferases EZH2, SMYD3 and SETDB1 and 
the histone demethylase LSD1, as well as the respective histone marks H3K9me3 and 
H3K27me3 in a series of CRC patients, clinically and pathologically well characterized, and to 
determine their value as biomarkers of prognosis and predictive of therapeutic response. 
A series of 98 colon cancer cases were randomly selected from the archives of 
Portuguese Oncology Institute-Porto between March 2003 and November 2006. The expression 
of EZH2, SETDB1, SMYD3 and LSD1, as well as the immunoreactivity of H3K9me3 and 
H3K27me3 were determined using immunohistochemical assays. The evaluation of SMYD3 
expression was considered positive if microscopic staining was present in >30% of the tumor 
cells. The remaining enzymes and both histone marks were assessed using a modified Histo-
score (H-score). Overall survival (OS) time was defined as the interval between surgery and 
death or between surgery and the last follow-up time for surviving patients. Survival rate curves 
were calculated according to the Kaplan-Meier method and compared by the log-rank test. 
Multivariate survival analyses were based on the Cox proportional hazard regression model. The 
level of significance was set at p < 0.05. 
 Considering the clinicopathological characteristics of the tumors included in this series, 
the occurrence of distant metastasis was independently associated with low survival rate, while 
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the occurrence of venous vessel invasion, positive margins, regional lymph node metastases and 
more advanced stage were associated with worse survival rates only in univariate analysis. 
Concerning the results of the immunohistochemical analysis, the histone 
methyltransferases EZH2 and SMYD3 and the histone demethylase LSD1 were overexpressed in 
CRC cells, suggesting a role for these enzymes in the neoplastic transformation. Interestingly, 
the expression of SMYD3 was detected in the cell membrane and cytoplasm of CRC cells, in 
contrast with the nuclear expression observed in the remaining histone modifying enzymes. In 
addition, the expression of histone marks H3K9me3 and H3K27me3 was increased in CRC cells, 
consistent with the increased expression of the abovementioned histone modifying enzymes. 
The expression of histone modifying enzymes and the expression of histone marks were 
associated with several clinocopathological features. Higher EZH2 expression was observed in 
more invasive CRCs and CRCs with regional lymph node metastases, suggesting that EZH2 may 
have a role in tumor growth and cell invasion. Higher SETDB1 expression was observed in left-
sided CRCs, suggesting a putative role in the carcinogenesis of chromossomic instable CRCs. 
Lower LSD1 expression was observed in more invasive CRCs and in CRCs at advanced stages 
of disease, suggesting that LSD1 may be associated with less aggressive CRCs. Higher 
H3K9me3 expression was observed in CRCs with regional lymph node metastases, which 
appears to be associated with the putative role of EZH2 in the progression of CRC. Higher 
H3K27me3 expression was observed in more invasive CRCs, CRCs with regional lymph node 
metastases and in CRCs at advanced stages of disease, as well as in CRCs with lymph and 
venous vessel invasion, which appears to be associated with the putative role of EZH2 in the 
progression of CRC. In this study we did not detected any differences in the survival rate of the 
patients with CRC considering the different expression of the studied histone modifying enzymes 
or histone marks. 
Regarding the response to treatment we observed higher survival rates in patients with 
CRCs treated only with surgery disclosing lower SETDB1 expression, suggesting that whenever 
the expression of SETDB1 occurs, the surgical treatment may not be enough to prolong the 
patient’s survival. Higher survival rates in patients with CRC treated with Folfiri were associated 
with high LSD1 and H3K9me3 expression in cancer cells, suggesting that LSD1 expression and 
the histone mark H3K9me3 can predict the response to this treatment modality. Higher survival 
rates of patients with CRC treated with 5-FU/Leucovorine were associated with high H3K9me3 
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and H3K27me3 expression in cancer cells, suggesting that these patterns of methylation can 
predict the response to this treatment modality. 
Finally, we verified that the evaluation of histone modifying enzymes and histone marks 
using a low/high expression system reproduced the results obtained with the H-score, 
constituting an easier system to evaluate the expression of the histone modifying enzymes and 
histone marks in the routine of a pathologist. 
This work accomplished the identification of new biomarkers that can be used in clinical 
practice and gives rise to new directions in the study of CRC carcinogenesis. 
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RESUMO 
O cancro colo-rectal (CCR) é a neoplasia com maior incidência e a segunda principal 
causa de morte por cancro em Portugal. O desfecho clínico do CCR é extremamente variável, o 
que torna importante subclassificar os pacientes com CCR no sentido de prever o prognóstico e a 
resposta à terapêutica. Vários estudos têm mostrado que a carcinogénese colo-rectal envolve não 
apenas alterações genéticas mas também modificações epigenéticas. Apesar de existirem vários 
tipos de modificações pós-tradução das histonas, apenas algumas têm sido relativamente bem 
estudadas, nomeadamente a acetilação e a metilação de histonas. Estas modificações são devidas 
à actividade de várias enzimas, como histonas metiltransferases e histonas demetilases, 
encontrando-se alterações nos seus níveis de expressão em várias neoplasias. Além disso, 
alterações nas marcas de histonas especificamente catalisadas pelas enzimas acima mencionadas, 
têm sido também associadas com vários tipos de tumores e ao seu prognóstico. 
O objetivo principal deste estudo foi caracterizar a expressão de quatro enzimas 
modificadoras de histonas, nomeadamente as histonas metiltransferases EZH2, SMYD3 e 
SETDB1 e a histona demetilase LSD1, bem como as respectivas marcas de histonas H3K9me3 e 
H3K27me3 numa série de pacientes com CCR, clinica e patologicamente bem caracterizados, e 
determinar o seu valor como biomarcadores de prognóstico e preditivos da resposta à terapêutica. 
Uma série de 98 casos de CCR foram selecionados aleatoriamente a partir dos arquivos 
do Instituto Português de Oncologia do Porto Francisco Gentil entre Março de 2003 e Novembro 
de 2006. A expressão de EZH2, SETDB1, SMYD3 e LSD1, bem como a imuno-reactividade de 
H3K9me3 e H3K27me3 foram determinadas usando métodos de imunohistoquímica. A 
avaliação da expressão de SMYD3 foi considerada positiva se a imuno-marcação estivesse 
presente em mais de 30% das células tumorais. As restantes enzimas e ambas as marcas de 
histonas foram avaliadas utilizando uma versão modificada do Histo-score (H-score). A 
sobrevivência global foi definida como o intervalo entre a cirurgia e a morte ou entre a cirurgia e 
a data da última consulta para os pacientes vivos. As curvas de sobrevida foram calculadas de 
acordo com o método de Kaplan-Meier e comparadas pelo teste de log-rank. A análise de 
sobrevivência multivariada foi baseada no modelo de regressão de risco proporcional de Cox. O 
nível de significância foi estabelecido em p <0,05. 
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Considerando as características clínico-patológicas dos tumores incluídos nesta série, a 
presença de metástases à distância foi independentemente associada com diminuição da 
sobrevivência, enquanto a presença de invasão venosa, margens positivas, metástase nos 
gânglios linfáticos regionais e estadio mais avançado foram associados com piores taxas de 
sobrevivência apenas na análise univariada. 
No que diz respeito aos resultados da análise imunohistoquímica, as histonas 
metiltransferases EZH2 e SMYD3 e a histone demetilase LSD1 encontravam-se sobre-expressas 
nas células do CCR, sugerindo um papel para estas enzimas na transformação neoplásica. 
Curiosamente, a expressão de SMYD3 foi detectada na membrana celular e no citoplasma das 
células do CCR, em contraste com a expressão nuclear observada nas restantes enzimas 
modificadoras de histonas. Além disso, a expressão das marcas de histonas H3K9me3 e 
H3K27me3 encontrava-se aumentada nas células do CCR, consistente com o aumento da 
expressão das referidas enzimas modificadoras de histonas. 
A expressão das enzimas modificadoras de histonas e a expressão das marcas de histonas 
encontraram-se associadas com várias características clínico-patológicas. Foi observada maior 
expressão de EZH2 nos casos mais invasivos e com envolvimento dos gânglios linfáticos 
regionais, o que sugere que a EZH2 pode ter um papel no crescimento e na invasão do tumor. Foi 
observada maior expressão de SETDB1 no CCR no cólon esquerdo, sugerindo um eventual 
papel na carcinogénese caracterizada pela instabilidade cromossómica. Foi observada menor 
expressão de LSD1 nos casos mais invasivos e nos casos em estadios avançados de doença, 
sugerindo que a LSD1 pode estar associada a casos menos agressivos. Foi observada maior 
expressão de H3K9me3 nos casos com envolvimento dos gânglios linfáticos regionais, que 
parece estar associada com a função proposta da EZH2 na progressão do CCR. Foi observado 
maior expressão de H3K27me3 nos casos mais invasivos, com envolvimento dos gânglios 
linfáticos regionais e nos casos com estadios mais avançados de doença, assim como nos casos 
com invasão linfática e venosa, o que parece estar associado com a função proposta da EZH2 na 
progressão do CCR. Neste estudo, não foi detectada nenhuma diferença na taxa de sobrevivência 
dos pacientes com CCR considerando a expressão das diferentes enzimas modificadoras de 
histonas ou da expressão de ambas as marcas de histonas. 
No que diz respeito à resposta ao tratamento, observou-se que a taxa de sobrevivência de 
pacientes com CCR tratados apenas com cirurgia era maior nos casos que apresentavam 
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diminuição da expressão de SETDB1, sugerindo que a expressão de SETDB1 agrava o 
prognóstico e que o tratamento cirúrgico pode não ser suficiente para prolongar a sobrevivência 
de pacientes. A taxa de sobrevivência era maior em pacientes com CCR tratados com FOLFIRI 
nos casos com maior expressão de LSD1 e H3K9me3, sugerindo que a expressão de LSD1 e de 
H3K9me3 pode prever a resposta a esta modalidade de tratamento. A taxa de sobrevivência era 
maior em pacientes com CCR tratados com 5-FU/Leucovorine nos casos com maior expressão 
de H3K9me3 e de H3K27me3, o que sugere que esses padrões de metilação podem prever a 
resposta a esta modalidade de tratamento. 
Finalmente verificou-se que a avaliação das enzimas modificadoras de histonas e da 
expressão de marcas de histonas utilizando um sistema de expressão em dois níveis reproduziu 
os resultados obtidos com o H-score, constituindo uma metodologia mais fácil de implementar 
na rotina de um patologista. 
Este trabalho permitiu a identificação de novos biomarcadores que podem ser utilizados 
na prática clínica e que estabelecem novas direcções no estudo da carcinogénese colo-rectal. 
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INTRODUCTION 
 
1. Epidemiology of colorectal cancer 
 In western world, cancer is a major public health problem. Although it affects both sexes, 
the lifetime probability of being diagnosed with an invasive cancer is slightly higher for men 
(45%) than for women (38%)24. The steady increase in the number of cancer cases diagnosed 
each year is thought to be due, mainly, to aging and growth of the population.25 Interestingly, the 
incidence rates have been decreasing since the 90s for all major cancer sites, except for breast 
cancer which remained relatively stable since 2005, and, more importantly, the cancer death rate 
has been decreasing since the beginning of the millennium.24 Nevertheless, cancer is the second 
leading cause of death, following cardiovascular diseases, accounting for 24% of all deaths.26 
Colorectal cancer (CRC) is one of the most common and well-studied malignancies, 
currently representing nearly 10% of all new cancers worldwide, being the fourth most frequent 
newly diagnosed cancer in men (after lung, prostate and gastric cancers), and the third in women 
(after cancers of the breast and uterine cervix). The worldwide mortality rate of CRC is nearly 
half of the incidence rate, but there is a wide variation in mortality rates according to the 
available treatment options.27 Decline in CRC incidence and death rates have been observed and 
have been attributed to a combination of screening programs and improvements in treatment28-30. 
The implementation of CRC screening tests allows the detection of CRC at an early stage of the 
disease and prevents cancer progression by promoting the removal of precancerous lesions.25 
However, only 60% of patients older than 50 years are in CRC screening programs, and, as a 
result, only 40% of CRC are diagnosed at a local stage, when treatment is most successful.31, 32 
The prevalence of sporadic CRC is higher in developed countries (nearly 50 per 100 000, 
as registered in Portugal), increases dramatically with age, being relatively uncommon before the 
fourth decade of life. The median age at diagnosis of CRC is 68 years for males and 72 years for 
females.32, 33 
In Portugal, CRC is the most incident cancer, representing nearly 15% of all cancers, and 
the second main cause of cancer-related deaths. In men, CRC is the second most commonly 
diagnosed cancer, after prostate cancer, and the second cause of cancer mortality, after lung 
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cancer. In women, CRC also ranks in the second position both for incidence and mortality rates, 
after breast cancer. Remarkably, in the north of Portugal CRC is the major cause of cancer-
related deaths in women.26, 33 
 
2. Etiology and pathogenesis of colorectal cancer 
CRC develops over long periods of time as the consequence of interactions between 
genetic predisposition and environmental factors. Among immigrants and their offspring, the 
incidence rates of CRC rapidly approach those of their adopted countries, indicating that 
lifestyle, dietary and other environmental factors are important risk factors.27 The majority of 
CRC are adenocarcinomas (more than 90%), which are thought to be originated in multipotential 
stem cells located in colorectal crypts from which precursor lesions may develop.34 CRC has 
been considered a genetic disease, characterized by sequential accumulation of genetic 
alterations. The identification of CRC genetic alterations has been facilitated by expression 
profile analysis, however the precise mechanisms underlying the majority of these genetic 
alterations, some of which are considered harmless passenger mutations with no selection 
advantage, remain unknown.27, 35, 36 
Many of the genes that are involved in CRC tumorigenesis have normal functions in 
signalling transduction pathways that regulate cell growth. The inadequate activation of such 
genes can lead to an inappropriate transmission of regulatory signals resulting in abnormal cell 
growth, some of which are elements of relevant signalling pathways, like the WNT, TGF/BMP, 
TP53, RTK and PI3K.37 
 
2.1 Colorectal cancer genetics 
Nearly 80% of CRCs are characterized by chromosome instability (CIN), showing gross 
chromosomal alterations (losses and gains) and aneuploid karyotype. The CIN is a type of 
genomic instability by which a cell is capable of acquiring cumulative genetic modifications that 
are thought to be essential to the malignant transformation of CRC. Additionally,the most 
frequent genetic alterations in CRC include mutations in APC, RAS, TP53, DCC and SMAD4 
genes. 
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The APC (adenomatous polyposis coli) was first discovered as the gene responsible for 
familial adenomatous polyposis (FAP), a form of hereditary CRC.38 One year later, this same 
gene was also found to be mutated in 60% of sporadic CRC. Indeed, the APC mutations can also 
be detected in CRC precursor lesions, showing a role in the early development of CRC.39 
Inactivation of both copies of the APC gene is a critical event in the initiation of adenoma 
lesions. The APC gene codifies a large protein with multiple domains and cellular functions that 
is expressed in the epithelium of the colon and rectum and which shows a increasing gradient 
from the bottom of the crypts to the luminal surface. APC is classically considered a tumor 
suppressor gene that downregulates the WNT signalling pathway by binding to β-catenin, 
resulting in the inhibition of cellular proliferation and differentiation.40 
Activating point mutations in a RAS gene have been detected in about 65% of sporadic 
CRC. As the majority of RAS mutations are thought to take place during intermediate stages of 
adenoma growth, other events are admitted to occur in order to promote CRC invasion and 
metastasis. RAS gene is an element of the mitogen-activated protein kinase pathway that can 
become constitutively activated in CRC not only due to RAS mutation but also by BRAF 
activating mutations, as an alternative mechanism. 
Other genetic modifications can take place later in the adenoma-to-carcinoma sequence 
of CRC, postulated by Vogelstein, namely TP53, DCC and SMAD4.41 
On the other hand, there is another type of genomic instability, named microsatellite 
instability (MSI), in which tumors remain diploid. MSI results from abnormal function in 
mismatch repair (MMR) genes, which lead to the accumulation of mutations in key genes, 
eventually resulting in malignancy. Germline mutations in MMR genes are found in hereditary 
non polyposis colon cancer/Lynch syndrome but also in sporadic CRC. Interestingly, most of 
sporadic tumors with MSI do not present mutations in the MMR genes, instead, MSI results from 
the epigenetic silencing of MMR genes, mostly through hypermethylation of the promoter of 
those genes.35 
 
2.2 Colorectal cancer epigenetics 
In the last decade, several studies have shown that carcinogenesis involves not only 
genetic alterations in oncogenes and tumor suppressor genes, but also epigenetic modifications.35 
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Epigenetic modifications are defined as heritable changes in gene expression that are not 
accompanied by changes in DNA sequence. These epigenetic alterations manifest both as global 
changes in chromatin packaging and localized alterations in binding of regulatory proteins to 
promoters, affecting transcription of genes critical to tumorigenesis. Epigenetic modifications 
involves aberrant DNA methylation, post-translational histone covalent modifications and 
microRNAs (miRNAs) altered expression42. 
One of the first epigenetic modifications described in CRC was global DNA hypomethylation,43 
that was found to be age dependent and an early event in the multistep carcinogenesis of CRC.44 
Global DNA hypomethylation occurs most frequently at CpG dinucleotides in repetitive 
sequences and in gene coding sequences, and less frequently in CpG islands and CpG island 
shores.45 Hypomethylation of DNA in CRC is thought to be associated to genomic instability of 
the CIN type, because loss of methylation at pericentromeric sites promote recombination and 
altered chromosome replications.46 
Alongside hypomethylation, hypermethylation has been also described in CRC, occurring 
preferentially at CpG islands in the 5´region of genes resulting in the silencing of gene 
expression. As a result, hypermethylation has the same outcome as a mutation or a deletion. 
Indeed, one example of promoter hypermethylation in the development of CRC is the biallelic 
methylation of MMR gene MLH1, which has been associated with sporadic CRC with MSI.36 
Additionally, a variety of post-translational histone modiﬁcations have been also 
implicated in the epigenetic regulation of gene expression through chromatin remodeling.47, 48 
Chromatin is composed of DNA and nuclear proteins including histones. The nucleosome is the 
fundamental unit of chromatin and it is composed of an octamer of the four core histones (H3, 
H4, H2A, H2B) around which base pairs of DNA are wrapped. The histones have long N-
terminal “tails” that are exposed to diverse covalent modifications: lysine acetylation, lysine and 
arginine methylation, serine and threonine phosphorylation, ADPribosylation, ubiquitylation, 
sumoylation, deimination and proline isomerization. Despite these different types of histone 
modifications, only a few have been relatively well studied, including acetylation and 
methylation.49 These mechanisms are able to regulate chromatin structure, therefore influencing 
the interaction with chromatin binding proteins and, ultimately, regulating gene expression.50 
The effects of post-translational histone modifications depend on the amino acid type, the 
position in the histone tail and the type of modification. Methylation of the histones at lysines or 
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arginines residues can be found in one of three different states: mono-, di- or trimethyl for 
lysines and mono- or di- (asymmetric or symmetric) for arginines. Moreover, histone modifying 
enzymes have selectivity for mono-, di- or trimethylated residues. Many of the above mentioned 
histone modifying enzymes has been shown to promote or inhibit tumorigenesis.51 All these add  
complexity to this type of epigenetic mechanism providing a huge potential for different 
functional control of transcription.49 There are two possible mechanisms by which histones 
regulate expression. One of the mechanisms is the disconnections of contacts within and between 
different histones in adjacent nucleosomes or between histones and DNA, which makes 
chromatin more accessible for transcription, and the other mechanism is the specific recruitment 
of nonhistone proteins.49 In addition, particular modifications of histone proteins are associated 
with alterations in other histone proteins, revealing a “crosstalk” between different histone 
modifications 47, 48 and even with DNA methylation status.52 
In general, acetylation of lysine residues of histones is related to the activation of 
transcription, whereas deacetylation of histones is associated with a repressive effect.53 
Methylation of histones can be either an effective activator or repressor of gene transcription 
depending on the location of lysine residues affected. Some of the histone modifications 
implicated in the activation of gene transcription are di and tri-methylation of H3K4, H3K36 and 
H3K79. On the other hand, histone modifications usually involved in the repression of gene 
transcription include methylation of H3K9, H3K27 and H4K20.49 
In cancer, it is known that those chromatin patterns alterations are attributed to the altered 
expression or activity of key chromatin-modifying enzymes. These alterations might be due to 
genetic alterations in genes codifying those enzymes.42, 53 Alterations in histone 
methyltransferases (such as EZH2, SETDB1 and SMYD3) and in histone demethylases (such as 
LSD1) expression levels have been found in several neoplasms.53 Furthermore, particular 
alterations in the pattern of the histone modifications (such as H3K9me3, H3K27me3 and 
H3K4me3) have been also associated with various types of tumors.42, 53 
H3K4 can be methylated or demethylated by several enzymes, the most studied of which 
are lysine methyltransferases MLL, SET1A/B and SMYD3 and lysine demethylases LSD1 and 
JARID1, respectively.49, 54 Methylation of H3K9 is performed mostly by members of the Suv39 
family, including SETDB1/2, SUV39H1/2, EHMT1/2, as well as non-Suv39 members such as 
PRDM2 and ASH1L.55 The reverse process is catalysed by the Jumonji (JMJ) family of histone 
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demethylases JMJD1A/B, JMJD2A/B, JMJD2C and JMJD2D.49 In a similar way, methylation of 
H3K27 is catalysed by histone methyltransferase EZH2 and its demethylation is catalysed by the 
JMJ family of histone demethylases KDM6A and KDM6B (JMJD3).56, 57 
Finally, the action of small noncoding miRNAs silences gene expression through 
translational repression, accelerated mRNA turnover and heterochromatin formation.58 as same 
as for other cancers, in CRC miRNAs affect the intracellular signaling pathways describe above, 
including WNT and TP53 signaling.36 Somatic alterations in miRNA-binding sites, affecting the 
action of miRNAs, has been reported in association with CRC risk59. Recently, mutations in the 
TARBP2, a protein involved in the processing of miRNAs, have been observed in CRC with 
MSI.60 
Two questions emerges when one think about all the epigenetic events occurring 
simultaneously in CRC – How are this events related? Which one is dominant?61 There has been 
some data referring that DNA methylation status is an important factor in the post-translational 
histone modifications.62 Silencing of miRNAs by promoter CpG island hypermethylation has 
also been reported. On the other hand, miRNAs are also capable, as described in plants, of 
transcriptional silencing in human CRC cells, directing promoter CpG hypermethylation and 
repressing gene expression.63 Hence, similarly to genetic mutations in DNA sequence, all of the 
above epigenetic mechanisms contribute to regulate gene transcription and can be responsible for 
the initiation and progression of tumorigenesis in CRC . 
Importantly, the interactions between genetic and epigenetic events should be also 
considered. Most of the epigenetic modifications end up targeting the same pathways as genetic 
alterations, eventually acting synergistically. In general, mutations and promoter 
hypermethylation are considered as mutually exclusive events.64 Genetic modifications capable 
of originating epigenetic events include the activation of oncogenic signaling pathways (like 
KRAS and c-MYC) and the initiation of promoter CpG methylation at specific loci.65, 66 
Moreover, single nucleotide polymorphisms (SNPs) might play a role in somatic epigenetic 
modifications, as reported for the MGMT promoter in CRC.67 Moreover, SNPs in the histone 
methyltransferase SMYD3 have been associated with CRC risk.68 Somatic modifications, 
including mutations and amplifications, in epigenetic proteins have been reported in CRC, 
namely in DNA methyltransferases, histone acetyltransferases and deacetylases, and histone 
methyltransferases, which can be also affected by promoter CpG island hypermethylation. 36 
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Additionally, epigenetic modifications originating genetic events include promoter CpG 
island hypermethylation of DNA repair genes MLH1 and MGMT giving rise to MSI and 
mutations in RAS and TP53, respectively.69, 70 
Therefore, cancer initiation and progression is a multistep process resulting from altered 
gene expression through genetic and epigenetic mechanisms, representing the new paradigm of 
carcinogenesis.71, 72 
 
3. Prognosis of colorectal cancer 
The relative survival rate for CRC patients is nearly 85% in the first year and 65% in the 
5th year after diagnosis. Indeed, the 5-year relative survival rate is as high as 90% when CRC is 
detected at a localized stage, declining to 70% and then to 12% , when the disease has spread to 
the regional lymph nodes, and to distant organs, respectivelly. Additionally, up to 40% of 
patients treated for local or locally advanced CRC will develop recurrence.25 
The most important prognostic factor in CRC is the tumor stage, which involves the 
degree of tumor invasion, regional lymph node metastasis and the presence of distant metastasis. 
Other clinicopathological factors have been considered useful in predicting clinical outcome, as 
the histological differentiation of the tumor and the existence of vascular invasion, including 
lymph and venous vessel invasion. Specifically, venous vessel invasion has been correlated, with 
local recurrence, distant metastases and decreased survival, whereas lymph vessel invasion has 
been associated only with a decreased survival. It is not clear whether lymph vessel invasion is 
an independent factor or if is related to tumor invasion or regional lymph node metastasis. All 
together, these factors are important in predicting patient survival and also in the implementation 
of the adequate therapy.41 
Surgical resection is the most elected treatment for CRC, in which the main objective is 
the complete removal of the tumor and the regional lymph nodes. Locally invasive CRC or  
regional lymph node metastastatic CRC correlate with high recurrence rates benefiting from an 
effective adjuvant therapy to eliminate the systemic cancer cells after surgery. The combination 
of chemotherapy and/or radiation therapy migh also be given to late-stage disease patients’ 
before surgery.25 The benefits of adjuvant chemotherapy in stage III patients has been 
conclusive, however the results were equivocal in stage II patients. The definition of the subset 
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of patients with stage II disease who will benefit from adjuvant therapy needs to be further 
studied. 
Due to the complexity of colon carcinogenesis the clinical outcome of CRC can vary 
significantly in cases with the same clinic-pathological characteristics. Hence, it is important to 
subclassify patients with CRC in order to better envisage the prognosis and treatment response. 
Several efforts have been taken in search for genetic prognostic factors in CRC as well as for 
epigenetic alterations that might be of prognostic value. Furthermore, disease progression is 
poorly understood and growing evidence indicates that epigenetic alterations add further 
complexity to the pathogenesis of CRC. Indeed, some epigenetic markers have been proposed to 
identify groups of patients with different prognosis and/or with different responses to treatment, 
particularly among patients with intermediate stages of disease, where management is by far 
more demanding.73 Namely, specific histone modifications have been recently shown to predict 
clinical outcome in multiple cancers, in which an association between histone modification 
levels and tumor aggressiveness, has been suggested regardless of cancer tissue of origin.36 
Seligson and collaborates showed that global histone modification patterns (H3K4me2 and 
H3K18ac), assessed by immunohistochemical staining, were predictive of clinical outcome in 
prostate cancer, identifying two groups of patients with distinct risk of recurrence.74 Two years 
later, using the same histone marks, they also found that those marks predicted clinical outcome 
in lung and kidney cancer patients.75 Moreover, Bianco-Miotto and collaborates established the 
same specific histone marks as independent predictors of clinical outcome in prostate cancer.76 
Elsheikh and collaborates identified variations in histone marks with clinical significance in 
invasive breast cancer, where high levels of histone acetylation (H3K9ac, H3K18ac and 
H4K12ac) and methylation (H3K4me2, H4K20me3 and H4R3me2) were associated with 
favorable prognosis.77 Moreover, expression of histone marks (H3K27me3 and H4K20me3) 
were  not only related with prognosis in breast, but also in ovarian, pancreatic and lung 
cancers.78, 79 Additionally, Barlesi and collaborates reported that in non small-cell lung cancer 
patients, different histone patterns (H2AK5ac and H3K9ac) were associated with different 
survival rates, providing a rationale for the use of a combination of standard chemotherapy with 
drugs interacting with histone modifications, namely histone deacetylase inhibitors.80 
Similar findings have been reported for digestive tract tumors , particularly for 
esophageal squamous cell carcinoma , in which specific expression  of H3K27me3 were found to 
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be independent predictors of survival.81 Furthermore, histone modifications might also predict 
response to certain therapeutic agents, serving as biomarkers that could inform clinical decisions 
on selecting therapy. Manuyakorn and collaborates found that cellular levels of histone 
modifications (H3K18ac, H3K4me2 and H3K9me2) might define previously unrecognized 
subsets of patients with pancreatic adenocarcinoma with distinct response to 5-FU, but not to 
gemcitabine. The clinical value of predicting response to therapeutics has tremendous 
implications for single or combinatorial therapies.82 In this regard, the use of genomic alterations 
as reliable biomakers for prediction of response to targeted therapy has been fully confirmed in 
CRC through the mutational analysis of K-RAS mutations.83  
 
Because histone onco-modifications seem to be highly conserved, they can be 
informative concerning prognosis and response to therapy in other cancers. Thus, there is a need 
to examine expression patterns of both histone covalent modifications and histone modifying 
enzymes, in CRC to define new prognostic markers and therapeutic targets.73 
Further improvements in the discovery of new epigenetic biomarkers can result in more 
sensitive and specific methods in noninvasive screening for early detection of CRC. The 
implementation of these new biomarkers in the clinical practice requires their validation in large 
independent prospective studies and the cost-effectiveness has to be compared with the screening 
tests already in use, like colonoscopy or fecal occult blood testing (FOBT). Moreover. new 
epigenetic biomarkers assessing the precise prognosis of each individual patient can optimize the 
therapeutic algorithm, which is particularly important in the stages of disease where decisions 
might be more complex. Accordingly, epigenetic biomarkers could predict the response to CRC 
therapy, establishing subgroups of patients in which the treatment of choice is more effective and 
opening the door for individualized therapy based on molecular profile. 
Importantly, the reversible nature of epigenetic alterations provides the opportunity for 
clinical intervention. The enzymes responsible for the modifications of epigenetic pathways 
represent interesting targets for new anti-cancer therapy. Understanding the most important 
interconnections between genetic and epigenetic modifications in gene expression and cancer 
phenotype will have a major impact in the development of new biomarkers for early detection, 
prediction of prognosis, response to treatment and creation of direct anti-cancer therapy. 72 
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However, epigenetic changes can potentially be reversed with inhibitors that block the relevant 
chromatin-modifying enzymes. Thus, it is important to better understand the role of these 
epigenetic enzymes in cancer cells with an ultimate goal of developing new cancer treatments. 
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AIM 
 
In the present work, the overall objective was to characterize the expression of histone 
modifying enzymes and histone marks in a series of CRC patients, clinically and pathologically 
well characterized, and to determine their value as biomarkers for assessment of prognosis and of 
prediction of therapeutic response. 
More specifically, the objectives of this study are: 
 
1 - Evaluate the expression of three histone methyltransferases (EZH2, SMYD3 and 
SETDB1), one histone demethylase (LSD1) and two histone marks (H3K9me3 and H3K27me3) 
in cancer tissue from patients with CRC using immunohistochemical methods. 
 
2 - Investigate the frequency of altered expression of the abovementioned enzymes and 
histone marks and further correlate them with clinicopathological data. 
 
3 - Determine the usefulness of the detection of the expression of the abovementioned 
histone modifying enzymes and histone marks as prognostic and predictive factors in CRC 
patients. 
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MATERIALS AND METHODS 
 
1. Tissue samples 
A series of 98 colon cancer cases were randomly selected from the archives of 
Portuguese Oncology Institute-Porto between March 2003 and November 2006. All patients 
were treated with surgery and none of the patients had any preoperative treatment, such as 
radiation or chemotherapy. 
The surgical specimens underwent pathological observation and all tissue samples were 
ﬁxed in 10% formalin and embedded in parafﬁn. The slides obtained from each paraffin block of 
each case were stained with hematoxilin-eosin. 
Clinicopathological information was obtained from clinical charts and pathological 
reports, referring to age at diagnosis, gender, tumor location, histological classification, grading, 
staging (depth of invasion, lymph node involvement and distant metastases), lymph vessel 
invasion, extramural venous vessel invasion and margins status. 
The tumors were classified according to the World Health Organization Classification of 
Tumours.27 The histological grade of tumor differentiation was determined using the College of 
American Pathology grading system. The clinical stage of tumors was defined according to the 
TNM classification system of the International Union Against Cancer (7th edition), which 
assesses the extension of the tumor (T), regional lymph node involvement (N) and the presence 
of distant metastases (M). Once the T, N and M classifications are determined, a stage of 0, I, II, 
III or IV is assigned. 
 
2. Immunohistochemical analysis and expression assessment 
The expression of four histone modifying enzymes, including three histone 
methyltransferases (EZH2, SMYD3 and SETDB1) and one histone demethylases (LSD1), and 
two histone marks (H3K9me3 and H3K27me3) were determined, by immunohistochemistry 
(IHC), in one representative block for each case. The selected paraffin block contained 
carcinoma and, whenever possible, apparently normal adjacent mucosa. IHC was performed 
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using the NovolinkTM Polymer Detection System (Novocastra, Newcastle, UK). Briefly, tissue 
sections of 3 µm in thickness were cut from each parafﬁn block. Deparaffinized tissue sections 
were submitted to antigen retrieval in a 700-W microwave oven, in respective buffer solution 
(Table 1). Endogenous peroxidase activity was blocked by incubating the slides with Peroxidase 
Block (Novocastra) for 5 min. After washing the slides in Tris-buffered solution with 0.05% 
Tween 20 solution (TBST), the slides were incubated with Protein Block (Novocastra) for 5 min 
and, after incubation, the primary antibody for each protein was applied in a humid chamber, at 
room temperature (Table 1). The slides were then rinsed in TBST and incubated with Post 
Primary Block (Novocastra) for 30 min followed by incubation for 30 min with the NovoLink 
Polymer (Novocastra). After washing, the slides were incubated for 7 min in 3,3-
diaminobenzidine (DAB; Sigma–Aldrich) in a solution of 50 mL PBS/0,05% mL H2O2. Finally, 
the slides were counterstained with hematoxylin (Harris Modified Hematoxylin Stain; Fisher 
Scientific, Fair Lawn, NJ, USA) for 20 s and mounted with Entellann (Merck KGaA, Darmstadt, 
Germany). 
 
Table 1. Optimized conditions for each antibody used in the immunohistochemistry analyses. 
Primary 
antibody 
Manufacturer 
Clone 
Positive control 
Retrival 
antigen 
Dilution 
Incubation 
period  
EZH2 Novocastra 6A10 Tonsil Citrato 1:1000 1h 
SETDB1 Sigma Polyclonal Colon Citrato 1:500 2h 
SMYD3 Abcam Polyclonal Seminal vesicles  Citrato 1:500 1h 
LSD1 
Novus 
Biologicals 
1B2F2 
ProstateCarcinoma  EDTA 1:1750 1h 
H3K27me3 Millipore Polyclonal Colon carcinoma  Citrato 1:1500 1h 
H3K9me3 Millipore CMA308 Colon carcinoma  Citrato 1:500 1h 
 
Assessment of antibody expression was performed using a semi-automated software 
system (CELLSENS® Imaging Software from Olympus). 
Immunohistochemical scoring of colon cancer cells was performed using the modified 
Histo-score (H-score), which involves quantitative assessment of both the intensity of staining 
(graded as 0 to 3) and the percentage of positive cells. The scores ranged from 0 to 300 enabling 
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us to stratify the cases into putative biologically relevant groups depending on different 
expression levels. Tumor samples with H-score <100 were designated as low detection, where 
scores >100 were designated high detection. In the specific case of SETDB1 expression, H-score 
was divided into low and high expression using the mean value. 
Concerning SMYD3 expression, qualitative evaluation was used by defining positive and 
negative expression. Immunostaining of more than 30% of the tumor cells was required for 
scoring a case as positive. Appropriate positive and negative internal controls were used to 
validate immunohistochemical expression. 
 
3. Statistical analysis 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS) version 20.0 for Windows. The Pearson´s chi-square (χ2) test or Fisher exact probability 
test were used for comparison of qualitative variables and the t-test or Mann-Whitney U test for 
quantitative variables. 
Univariate analyses of time to death as a result of cancer were performed using the 
Kaplan-Meier method. Survival rate curves were calculated according to the Kaplan-Meier 
method and compared by the log-rank test. Multivariate survival analyses were based on the Cox 
proportional hazard regression model. 
The date of resection was considered day zero for survival analysis purposes. The 
terminal event for cancer-related survival was death attributable only to cancer. Overall survival 
(OS) time was defined as the interval between surgery and death or between surgery and the last 
follow-up time for surviving patients. The level of significance was set at p < 0.05 and the 
Bonferroni’s correction was used when appropriate. 
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RESULTS 
 
1. Clinicopathological parameters and survival analysis 
In the 3-year and 8 month-period covered by this study, 98 randomly cases of CRC were 
retrieved from the archives of Portuguese Oncology Institute-Porto. Of the 98 CRC cases, 48% 
(n=47) were diagnosed in women and 52% (n=51) in men, with a median age at diagnosis of 
68.5 years (69 years for men and 66 years for women). Median follow-up time was 77.5 months 
(range, 3-111 months). More than half of the cases (71.4%) were identified in the left colon 
(n=70). The cases were classified as adenocarcinomas and the percentage with tubular pattern 
was 94.9% (n=93) whereas the mucinous pattern was observed in 5.1% (n=5) of the cases. The 
adenocarcinomas with tubular pattern were graded as low-grade (90.3%) or high-grade (9.7%). 
Lymph vessel invasion was observed in 41.8% (n=41) and venous vessel invasion in 28.6% 
(n=28) of cases. Additionally, tumor involvement of at least one of the surgical margins was 
recorded in only 3.1% of the cases. From the selected CRC cases, 28.6% (n=28) were diagnosed 
at a localized stage, 50% (n=49) displayed lymph node metastases and 27.6% (n=27) displayed 
distant metastases at the time of diagnosis or later. Metastases were identified mainly in the liver 
(46.5%), peritoneum (23.3%) and lung (9.3%). The main clinicopathological features of the 98 
selected CRC cases are depicted in Table 2. 
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Table 2. Clinicopathological features of the CRC cases. 
Clinicopathological features % of cases (number of cases) 
Age a 
    ≤67 years 
    >67 years 
 
45.9% (45) 
54.1% (53) 
Gender 
    Female 
    Male 
 
48% (47) 
52% (51) 
Tumor location 
    Cecum 
    Ascending colon 
    Hepatic flexure 
    Transverse colon 
    Splenic flexure 
    Descending colon 
    Sigmoid colon 
 
12.2% (12) 
10.2% (10) 
5.1% (5) 
1% (1) 
7.1% (7) 
6.1% (6) 
58.2% (57) 
Tumor pattern 
    Tubular 
    Mucinous 
 
94.9% (93) 
5.1 (5) 
Tumor grading 
    Low grade 
    High grade 
 
90.3% (84) 
9.7% (9) 
Lymph vessel invasion 
    Not observed 
    Observed 
 
58.2% (57) 
41.8% (41) 
Venous vessel invasion 
    Not observed 
    Observed 
 
71.4% (70) 
28.6% (28) 
Margins status 
    R0 
    R1 
    R2 
 
96.9% (95) 
1% (1) 
2% (2) 
pT 
    T1 
    T2 
    T3 
    T4a 
    T4b 
 
5.1% (5) 
23.5% (23) 
57.1% (56) 
3.1% (3) 
11.2% (11) 
pN 
    N0 
    N1a 
    N1b 
    N2a 
    N2b 
 
50% (49) 
12.2% (12) 
18.4% (18) 
11.2% (11) 
8.2% (8) 
pM 
    M0 
    M1a 
    M1b 
 
74.5% (79) 
12.3% (13) 
13.2% (14) 
pTNM Stage 
    I 
    II 
    III 
    IV 
 
25.5% (25) 
16.3% (16) 
30.6% (30) 
27.6% (27) 
33 
 
The overall survival rate of the 98 patients was 95.9% and 73.5% at one and five years of 
follow-up, respectively. Univariate survival analysis showed a significant association between a 
decrease in overall survival and the occurrence of venous vessel invasion (ρ=0.003), positive 
surgical margins (ρ=0.009), regional lymph node metastasis (ρ=0.011) and distant metastasis 
(ρ<0.001), as well as with tumor stage III or IV (ρ=0.004). The remaining parameters were not 
significantly associated with overall survival (Table 3). 
 
Table 3. Univariate analyses of the association between clinicopathological 
features and overall survivala. 
Clinicopathological features Mean (months) ρb 
Age (≤67 years/>67 years) c 90.800/87.075 ns 
Gender (female/male) 86.617/90.784 ns 
Tumor location (right/left) 90.214/87.914 ns 
Tumor pattern (tubular/mucinous) 88.323/79.800 ns 
Tumor grade (low/high) 87.167/99.111 ns 
Lymph vessel invasion (no/yes) 92.175/83.024 ns 
Venous vessel invasion (no/yes) 95.943/70.893 0.003 
Margins status (R0/R1+R2) 90.232/32.000 0.009 
pT (T1+T2/T3+T4) 97.429/85.000 ns 
pN (N0/N1+N2) 98.551/79.020 0.011 
pM (M0/M1) 97.268/65.037 <0.001 
pTNM Stage (I+II/III+IV) 101.756/79.456 0.004 
ns – not significant 
a Kaplan-Meier method was used 
b Log-rank ρ-value 
c Mean age at the time of diagnosis 
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In multivariate analysis, using Cox proportional hazard regression model, only the M 
stage was independently associated with decreased overall survival (ρ=0.011) whereas a trend 
for lower survival was depicted for patients with positive surgical margins (ρ=0.058) (Table 4). 
 
Table 4. Multivariate analyses of the association between clinicopathological features 
and overall survivala. 
Clinicopathological features Hazard ratio (95% CI) ρ 
Venous vessel invasion (no/yes) 1.695 (0.724-3.699) ns 
Margins status (R0/R1+R2) 4.521 (0.949-21.545) ns 
pN (N0/N1+N2) 2.102 (0.583-7.576) ns 
pM (M0/M1) 3.465 (1.332-9.011) 0.011 
pTNM Stage (I+II/III+IV) 0.755 (0.127-4.485) ns 
CI - confidence interval 
ns – not significant 
a Cox proportional survival regression model was used 
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2. Immunohistochemical analyses 
 Considering the histone modifying enzymes, the expression of EZH2, SETDB1 and 
LSD1 were only observed in the nuclei of the cells, whilst the expression of SMYD3 was 
detected both in the cytoplasm and cell membrane. All enzymes, excepting for SETDB1, showed 
higher expression in tumor cells than in epithelial cells of the adjacent normal mucosa (Table 5a 
and 5b). Immunoreactivity for both histone marks, H3K9me3 and H3K27me3, was only found in 
nuclei. The highest expression was observed in the tumor cells (Table 5a), which displayed a 
rather homogenous pattern of staining. 
 
Table 5a. Differences between the expression of the selected 
enzymes or histone marks in the nuclei of tumor cells and their 
expression in the normal mucosa. 
Enzyme/Mark 
Topography of the expression 
(mean±sd) 
 
Normal mucosa Tumor cells ρ 
EZH2 39.199±26.676 82.328±55.272 <0.001a 
SETDB1 50.319±9.788 47.822±19.557 ns b 
LSD1 141.861±19.325 211.020±71.787 <0.001a 
H3K9me3 97.713±67.500 176.884±85.452 <0.001b 
H3K27me3 58.434±12.568 135.228±63.274 <0.001b 
sd – standard deviation 
ns – not significant 
a Mann-Whitney U test 
b t test 
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Table 5b. Differences between the expression of SMYD3 in the 
cytoplasm and cell membrane of tumor cells and its expression in the 
normal mucosa. 
Enzyme 
Topography of the expression 
(% of positive cases) 
 
Normal mucosa Tumor cells ρ 
SMYD3 0 100 <0.001a 
a Pearson Chi-Square 
 
Table 5c. Univariate analyses of the association between the expression 
of the selected enzymes or histone marks in CRC and respective overall 
survivala. 
Enzyme/Mark Mean (months) pb 
EZH2 (low/high) 90.254/86.143 ns 
SETDB1 (low/high) 91.254/83.897 ns 
LSD1 (low/high) 86.333/88.798 ns 
H3K9me3 (low/high) 82.542/90.162 ns 
H3K27me3 (low/high) 96.233/85.147 ns 
ns – not significant 
a Kaplan-Meier method was used 
b Log-rank ρ-value  
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Table 5d. Univariate analyses of the association between the expression of the selected enzymes 
or histone marks in CRC with different therapeutics and respective overall survivala. 
Enzyme/Mark 
Mean – months (ρb) 
Treatment 
Surgery 
Surgery 
+ 5-FU/Leucovorine  
Surgery 
+ Folfiri 
Surgery 
+ Folfox 
EZH2 
(low/high) 
104.778/95.143 
(ns) 
78.800/86.000 
(ns) 
36.750/31.250 
(ns) 
64.214/79.467 
(ns) 
SETDB1 
(low/high) 
106.500/91.867 
(0.034) 
NC 28.667/37.200 
(ns) 
70.000/69.333 
(ns) 
LSD1 
(low/high) 
NC NC 18.000/36.286 
(0.008) 
64.500/77.880 
(ns) 
H3K9me3 
(low/high) 
94.182/102.733 
(ns) 
24.000/92.250 
(0.005) 
20.500/38.500 
(0.019) 
48.667/83.174 
(ns) 
H3K27me3 
(low/high) 
105.813/98.560 
(ns) 
32.000/99.714 
(0.018) 
32.000/34.286 
(ns) 
NC 
NC – not computed 
ns – not significant 
a Kaplan-Meier method was used 
b Log-rank ρ-value 
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2.1. EZH2 expression in CRC cases 
The immunoexpression of EZH2 in CRC cases is detailed in table 6. EZH2 score ranged 
from 0 to 274.6 (median: 56.1) and 35 cases (35.7%) disclosed high expression score. EZH2 
expression was significantly higher in deeply invasive CRCs (pT3 and pT4) (ρ=0.004) and in 
CRCs with lymph node metastasis (pN1 or pN2) (ρ=0.019). The number of cases with low 
expression of EZH2 was higher in tumors located in the left colon (ρ=0.020). EZH2 expression 
was neither associated with overall survival rate of the CRC patients (Table 5c) nor with survival 
rate amongst patients treated with different chemotherapy regimens (Table 5d). 
Figure 1 – EZH2 expression in normal mucosa (A) 
and in CRC cells (B). 
A B 
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Table 6. Analyses of the association between clinicopathological features and EZH2 expression. 
Clinicopathological 
features 
EZH2 expression 
(mean±sd) p
 b EZH2 low/high expression (number of cases) p 
Age a 
≤67 years 
 >67 years  
88.348±54.527 
77.217±55.901 
ns 27/18 
36/17 
ns c 
Gender  
Female 
Male 
84.204±53.484 
80.600±57.347 
ns 29/18 
34/17 
ns c 
Tumor location  
Right 
Left 
98.853±67.907 
75.718±48.323 
ns 13/15 
50/20 
0.020c 
Tumor pattern  
Tubular 
Mucinous 
80.768±54.641 
111.356±65.592 
ns 62/31 
1/4 
ns d 
Tumor grading  
Low 
High 
81.468±55.382 
74.234±49.600 
ns 56/28 
6/3 
ns d 
Lymph vessel invasion  
No 
Yes 
71.646±49.575 
97.179±59.824 
ns 41/16 
22/19 
ns c 
Venous vessel invasion  
No 
Yes 
77.837±55.214 
93.556±54.786 
ns 48/22 
15/13 
ns c 
Margins status  
R0 
R1+R2 
83.262±55.888 
52.760±3.311 
ns 60/35 
3/0 
ns d 
pT  
T1+T2 
T3+T4 
59.045±43.727 
91.641±56.908 
0.004 23/5 
40/30 
0.020c 
pN  
N0 
N1+N2 
72.138±56.749 
92.518±52.356 
0.019 35/14 
28/21 
ns c 
pM  
M0 
M1 
86.826±57.105 
70.500±49.167 
ns 43/28 
20/7 
ns c 
pTNM Stage  
I+II 
III+IV 
78.417±59.696 
85.142±52.220 
ns 27/14 
36/21 
ns c 
ns – not significant 
a Mean age at the time of diagnosis 
b Mann-Whitney U test 
c Pearson Chi-Square 
d Fisher´s Exact test 
 
40 
 
2.2. SETDB1 expression in CRC cases 
 The immunoexpression of SETDB1 in CRC cases are disclosed in table 7. SETDB1 score 
ranged from 5.9 to 98.9 (median: 43.4) and high expression was observed in 39 cases (39.8%). 
SETDB1 expression was significantly higher in CRCs located in the left colon compared to those 
located in the right colon (ρ=0.032). SETDB1 expression was not associated with overall 
survival rate of the CRC patients (Table 5c). However, high SETDB1 expression was associated 
with poorer survival rate within patients treated with only surgery (stages I and II) (ρ=0.034) 
(Table 5d). 
Figure 2 – SETDB1 expression in normal mucosa 
(A) and in CRC cells (B). 
A B 
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Table 7. Analyses of the association between clinicopathological features and SETDB1 expression. 
Clinicopathological 
features 
SETDB1 expression 
(mean±sd) p
 b SETDB1 low/high expression (number of cases) p
  
Age a 
≤67 years 
 >67 years  
49.854±19.414 
46.098±19.696 
ns 26/19 
33/20 
ns c 
Gender  
Female 
Male 
45.227±20.078 
50.215±18.946 
ns 31/16 
28/23 
ns c 
Tumor location  
Right 
Left 
41.142±17.729 
50.494±19.732 
0.032 20/8 
39/31 
ns c 
Tumor pattern  
Tubular 
Mucinous 
47.131±19.399 
60.690±20.049 
ns 58/35 
1/4 
ns d 
Tumor grading  
Low 
High 
47.283±19.800 
45.706±16.044 
ns 53/31 
5/4 
ns c 
Lymph vessel invasion  
No 
Yes 
44.991±18.040 
51.759±21.085 
ns 36/21 
23/18 
ns c 
Venous vessel invasion  
No 
Yes 
46.380±18.641 
51.429±21.615 
ns 44/26 
15/13 
ns c 
Margins status  
R0 
R1+R2 
47.941±19.766 
44.063±12.884 
ns 57/38 
2/1 
ns d 
pT  
T1+T2 
T3+T4 
46.445±16.950 
48.373±20.596 
ns 18/10 
41/29 
ns c 
pN  
N0 
N1+N2 
45.241±16.705 
50.403±21.915 
ns 30/19 
29/20 
ns c 
pM  
M0 
M1 
46.922±19.232 
50.191±20.569 
ns 44/27 
15/12 
ns c 
pTNM Stage  
I+II 
III+IV 
45.301±17.918 
49.636±20.620 
ns 26/15 
33/24 
ns c 
ns – not significant 
a Mean age at the time of diagnosis 
b t test 
c Pearson Chi-Square 
d Fisher´s Exact test 
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2.3. SMYD3 expression in CRC cases 
 SMYD3 expression was positive in all CRC cases and no association with standard 
clinicopathological features was disclosed. 
Figure 3 – SMYD3 expression in normal mucosa 
(A) and in CRC cells (B). 
A B 
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2.4. LSD1 expression in CRC cases 
 Table 8 summarizes the immunohistochemical expression of LSD1 in the 98 CRC cases. 
LSD1 score ranged from 0 to 297.5 (median: 238) and 89 cases (90.8%) disclosed 
overexpression. LSD1 expression was significantly lower in deeply invasive (pT3 and pT4) and 
advanced stage (stages III and IV) tumors (ρ=0.016 and ρ=0.009, respectively). LSD1 expression 
was not associated with overall survival rate of the CRC patients (Table 5c). However, high 
LSD1 expression was associated with better survival rate within patients treated with Folfiri 
(ρ=0.008) (Table 5d). 
Figure 4 – LSD1 expression in normal mucosa (A) 
and in CRC cells (B). 
A B 
44 
 
 
Table 8. Analyses of the association between clinicopathological features and LSD1 expression. 
Clinicopathological 
features 
LSD1 expression 
(mean±sd) p
 b LSD1 low/high expression (number of cases) p
c 
Age a 
≤67 years 
 >67 years  
200.507±76.918 
219.945±66.559 
ns 6/39 
3/50 
ns 
Gender  
Female 
Male 
204.560±77.242 
216.972±66.582 
ns 5/42 
4/47 
ns 
Tumor location  
Right 
Left 
207.653±82.894 
212.366±67.449 
ns 4/24 
5/65 
ns 
Tumor pattern  
Tubular 
Mucinous 
210.521±71.708 
220.284±81.171 
ns 8/85 
¼ 
ns 
Tumor grading  
Low 
High 
209.816±73.610 
217.102±53.517 
ns 8/76 
0/9 
ns 
Lymph vessel invasion  
No 
Yes 
215.934±64.608 
204.188±81.061 
ns 3/54 
6/35 
ns 
Venous vessel invasion  
No 
Yes 
213.625±71.607 
204.505±73.135 
ns 6/64 
3/25 
ns 
Margins status  
R0 
R1+R2 
211.619±72.229 
192.027±64.658 
ns 9/86 
0/3 
ns 
pT  
T1+T2 
T3+T4 
238.029±56.619 
200.216±74.671 
0.016 0/28 
9/61 
ns 
pN  
N0 
N1+N2 
222.240±63.225 
199.799±78.484 
ns 2/47 
7/42 
ns 
pM  
M0 
M1 
218.059±70.039 
192.507±74.349 
ns 5/66 
4/23 
ns 
pTNM Stage  
I+II 
III+IV 
234.346±54.849 
194.241±78.055 
0.009 0/41 
9/48 
0.009 
ns – not significant 
a Mean age at the time of diagnosis 
b Mann-Whitney U test 
cFisher´s Exact test 
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2.5. H3K9me3 expression in CRC cases 
 The immunoexpression of H3K9me3 in CRC cases is presented in table 9. H3K9me3 
immunoreactivity score ranged from 0 to 299.7 (median: 173.1) and 74 cases (75.5%) disclosed 
high expression. The expression of H3K9me3 in CRC was significantly higher in those with 
lymph node metastases (pN1 or pN2) (ρ=0.044). H3K9me3 expression was not associated with 
overall survival rate of the CRC patients (Table 5c). However, high H3K9me3 expression was 
associated with better survival rate within patients treated with 5-FU/Leucovorine and Folfiri 
(ρ=0.005 and ρ=0.019, respectively) (Table 5d). 
Figure 5 – H3K9me3 expression in normal mucosa 
(A) and in CRC cells (B). 
A B 
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Table 9. Analyses of the association between clinicopathological features and H3K9me3 immunoreactivity. 
Clinicopathological 
features 
H3K9me3 expression 
(mean±sd) p
 b H3K9me3 low/high expression (number of cases) p
  
Age a 
≤67 years 
 >67 years  
167.744±86.688 
184.645±84.431 
ns 12/33 
12/41 
ns c 
Gender  
Female 
Male 
168.943±81.639 
184.203±88.996 
ns 12/35 
12/39 
ns c 
Tumor location  
Right 
Left 
173.921±77.951 
178.070±88.783 
ns 7/21 
17/53 
ns c 
Tumor pattern  
Tubular 
Mucinous 
178.672±84.543 
143.642±105.948 
ns 23/70 
¼ 
ns d 
Tumor grading  
Low 
High 
179.561±86.555 
170.372±66.211 
ns 21/63 
2/7 
ns d 
Lymph vessel invasion  
No 
Yes 
174.401±89.373 
180.337±80.646 
ns 15/42 
9/32 
ns c 
Venous vessel invasion  
No 
Yes 
174.842±88.226 
181.991±79.393 
ns 18/52 
6/22 
ns c 
Margins status  
R0 
R1+R2 
176.071±84.927 
202.657±118.866 
ns 23/72 
½ 
ns d 
pT  
T1+T2 
T3+T4 
170.245±97.977 
179.540±80.522 
ns 9/19 
15/55 
ns c 
pN  
N0 
N1+N2 
159.539±95.177 
194.230±71.297 
0.044 17/32 
7/42 
0.019 c 
pM  
M0 
M1 
183.038±85.622 
160.702±84.434 
ns 15/56 
9/18 
ns c 
pTNM Stage  
I+II 
III+IV 
171.128±92.857 
181.025±80.297 
ns 11/30 
13/44 
ns c 
ns – not significant 
a Mean age at the time of diagnosis 
b t test 
c Pearson Chi-Square 
d Fisher´s Exact test 
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2.6. H3K27me3 expression in CRC cases 
 The immunoexpression of H3K27me3 in CRC cases is reported in table 10. Concerning 
H3K27me3 imunoreactivity, the score ranged from 0 to 298.3 (median: 141.7) and 68 cases 
(69.4%) disclosed high expression (Table 10). The expression of H3K27me3 in CRC was 
significantly higher in tumors that presented lymph vessel invasion (ρ=0.041). The number of 
CRC cases with high immunoreactivity for H3k27me3 was higher in CRC cases with venous 
vessel invasion (ρ=0.027). H3K27me3 immunoreactivity was significantly higher in deeply 
invasive CRCs (pT3 and pT4) and in CRCs with lymph node metastases (pN1 and pN2) 
(ρ=0.007 and ρ=0.000, respectively), as well as in advanced stage (III and IV) tumors (ρ=0.014). 
H3K27me3 expression was not associated with overall survival rate of the CRC patients (Table 
5c). However, high H3K27me3 expression was associated with better survival rate within 
patients treated with 5-FU/Leucovorine (ρ=0.018) (Table 5d). 
Figure 6 – H3K27me3 expression in normal 
mucosa (A) and in CRC cells (B). 
A B 
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Table 10. Analyses of the association between clinicopathological features and H3K27me3 immunoreactivity. 
Clinicopathological 
features 
H3K27me3 expression 
(mean±sd) p
 b H3K27me3 low/high expression (number of cases) p
  
Age a 
≤67 years 
 >67 years  
133.696±63.317 
136.529±63.814 
ns 13/32 
17/36 
ns c  
Gender  
Female 
Male 
 
131.713±63.567 
138.468±63.460 
ns 17/30 
13/38 
ns c  
Tumor location  
Right 
Left 
136.894±60.764 
134.562±64.668 
ns 8/20 
22/48 
ns c 
Tumor pattern  
Tubular 
Mucinous 
134.737±64.107 
144.368±49.556 
ns 29/64 
1/4 
ns d 
Tumor grading  
Low 
High 
137.074±64.404 
112.929±60.288 
ns 24/60 
5/4 
ns d 
Lymph vessel invasion  
No 
Yes 
124.187±63.702 
150.578±60.104 
0.041 21/36 
9/32 
ns c 
Venous vessel invasion  
No 
Yes 
129.249±68.724 
150.176±44.600 
ns 26/44 
4/24 
0.027 c 
Margins status  
R0 
R1+R2 
134.099±63.828 
170.980±26.769 
ns 30/65 
0/3 
ns d 
pT  
T1+T2 
T3+T4 
108.333±60.343 
145.987±61.583 
0.007 13/15 
17/53 
0.032 c 
pN  
N0 
N1+N2 
111.134±58.244 
159.322±59.271 
0.000 22/27 
8/41 
0.002 c 
pM  
M0 
M1 
135.295±63.034 
135.043±65.111 
ns 20/51 
10/17 
ns c 
pTNM Stage  
I+II 
III+IV 
116.848±59.342 
148.449±63.200 
0.014 16/25 
14/43 
ns c 
ns – not significant 
a Mean age at the time of diagnosis 
b t test 
c Pearson Chi-Square 
d Fisher´s Exact test 
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3. Evaluation of the association between histone modifying enzymes and 
histone marks 
High levels of EZH2 expression were associated with high levels of H3K9me3 and 
H3K27me3 immunoreactivity in tumor cells (Pearson correlation=0.362; ρ<0.001 and Pearson 
correlation=0.311; ρ=0.002, respectively). Moreover, SETDB1 expression was not associated 
with H3K9me3 immunoreactivity (Pearson correlation=-0.019; ρ=ns). Finally, high levels of 
H3K9me3 immunoreactivity were associated with high H3K27me3 immunoreactivity in CRC 
cases (Pearson correlation=0.542; ρ<0.001). 
Figure 7 – Correlation of EZH2 expression with H3K9me3 expression (A) and H3K27me3 
expression (B). 
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DISCUSSION 
In the present study we aimed at the characterization of the patterns of expression of 
histone modifying enzymes and histone marks in a series of 98 CRC patients, well characterized 
both clinically and pathologically, to determine their value as biomarkers for assessment of 
prognosis and of prediction of therapeutic response. We found that the occurrence of distant 
metastasis was independently associated to low survival rate of CRC patients. The histone 
methyltransferases EZH2 and SMYD3 and the histone demethylase LSD1 were overexpressed in 
CRC cells, as well as the immunoreactivity of histone marks H3K9me3 and H3K27me3. The 
expression of histone modifying enzymes and the expression of histone marks were associated 
with several clinocopathological features, including lymph and venous vessel invasion, depth of 
invasion, regional lymph node metastases and clinical stage. Regarding the response to 
treatment, we observed higher survival rates for patients with CRCs treated only with surgery 
disclosing lower SETDB1 expression and higher survival rates for patients with CRC treated 
with Folfiri or 5-FU/Leucovorine disclosing high LSD1 and H3K9me3 expression or high 
H3K9me3 and H3K27me3 expression in cancer cells, respectively. 
 
1. Clinicopathological features and patient outcome 
The clinicopathological features of our series of CRCs are consistent with the features of 
other CRC series reported in the literature, with the exception of a lower median age at the 
diagnosis in female patients, which is 66 years compared with 72 years reported in larger 
series.32, 84-86 In addition, the number of low grade and stage I CRCs in our series was higher than 
in other larger reported series.84 Because our series is composed of cases admitted for primary 
surgical treatment at Portuguese Oncology Institute-Porto, it is likely that these discrepancies 
merely reflect a different profile of CRCs in different populations. There are not, however, 
similar series from other Portuguese healthcare institutions with which we could compare our 
cases to definitely clarify these findings. 
 Several standard clinicopathological parameters have been previously described to be 
associated to CRC prognosis including age, gender, tumor grading, lymph vessel invasion, 
venous vessel invasion, lymph node metastases, distant metastases and staging.84, 86 Although in 
our series many of those parameters were of prognostic significance in univariate analysis, only 
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the occurrence of distant metastasis was independently associated to lower survival rate. This 
result is probably derived from the relatively small size of our series, which impacts negatively 
on statistical analysis. Thus, an extension of the number of cases enrolled in this study should be 
considered. 
 In comparison with a larger series reported by Siegel and collaborators, that documented 
a survival rate of 85% in the first year and 65% in the fifth year25, we observed survival rates of 
95.9% in the first year and 73.5% in the fifth year in our series, probably reflecting the higher 
proportion of low grade and low stage CRC, as previously mentioned. Indeed, localized stage 
CRC had a 5-year survival rate of 88% but when regional lymph node involvement was present, 
the 5-year survival rate decreased to 61.2%, in line with other series.25 
 
2. Expression of histone methyltransferases and demethylases in CRC 
Concerning immunohistochemical analysis, we observed that expression of the histone 
modifying enzymes EZH2, SMYD3, and LSD1 in CRC cells were significantly higher than in 
the adjacent, morphologically normal colonic mucosa, suggesting a role for these enzymes in the 
neoplastic transformation of colorectal mucosa cells. Importantly, the expression of both 
H3K9me3 and H3K27me3 was significantly associated with the increased of EZH2 expression. 
Because EZH2 is the enzyme responsible for these two repressive marks, we might postulate that 
EZH2 overexpression translates into dysfunctional expression of specific genes in CRC. In fact, 
EZH2 is a member of the Polycomb group (PcG) proteins involved in cell cycle regulation and 
proliferation. EZH2 catalyzes the subunit of the polycomb-repressor complex (PRC) by 
methylating lysine 9 and 27 of histone H3. Thus, polycomb target genes are often silenced by 
histone deacetylation and DNA methylation of CpG islands owing to the ability of PcG proteins 
to bind to histone deacetylases (HDAC) and recruit DNA methyltransferases (DNMT)87, thereby 
reducing gene expression in various tissues. Hence, both histone methylation induced by EZH2, 
histone deacetylation induced by HDAC and DNA promoter methylation induced by DNMT 
play a synergistic role in gene expression silencing. Although high levels of EZH2 expression 
were significantly associated with increased H3K9me3 and H3K27me3 expression, variations in 
EZH2 expression only explain approximately 13% of the variability of H3K9 expression and 
10% of the variability of H3K27 expression. Thus, other factors are likely to play an important 
role in the H3K9 and H3K27 methylation in CRC, including regulators of EZH2 activity, other 
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histone methyltransferases, such as SUV39H1/2, EHMT1/2 or PRDM2, or even histone 
demethylases, such as JMJD1A/B, JMJD2A/B or JMJD3. 
Recently, several studies have demonstrated that EZH2 expression is commonly 
upregulated in several solid tumors, including those of colon88, breast89, 90, bladder91, 92, 
prostate93, gastric 94, liver95, lung96, skin and soft tissue sarcomas97, as well as in lymphoma.98-101 
Additionally, high expression levels of EZH2 have been associated with increased cell 
proliferation, whilst its inhibition led to growth arrest in various cancer cell lines, including colon 
cancer cell lines.88, 102 Therefore, inhibition of EZH2 expression has been proposed to inhibit 
tumor progression.53 Interestingly, we found that EZH2 was highly expressed in the more 
invasive CRCs as well as in cases with lymph node metastasis. These results are consistent with 
previous studies suggesting a relationship between EZH2 expression, tumor growth and cell 
invasion in CRC.94 Remarkably, EZH2 high expression levels have been found to be associated 
with tumor progression and poor prognosis in prostate, breast, gastric, skin and non-small lung 
cancer.89, 93, 94, 96, 103-105 Contrarily, in CRC high EZH2 expression levels were independently 
associated with a better prognosis.96, 106 In our study, EZH2 expression was neither associated 
with overall survival rate nor with survival rate amongst patients treated with the therapeutical 
agents previously described, and, thus, no definitive conclusions about the prognostic value of 
EZH2 in CRC can be drawn. 
The previous findings of the association between increased EZH2 levels and better 
prognosis is CRC are difficult to explain biologically. Indeed, EZH2 is controlled by the E2F 
transcription factors that regulate the transition from G2 to the mitotic phase of the cell cycle by 
increasing the expression of cyclin E.107, 108 Although the downstream signaling of EZH2 in 
neoplasia is poorly understood, apparently EZH2 is able to reduce the transcriptional repression 
of the cyclin A promoter by competing with HDAC1109. This reveals a critical role in the 
regulation of cyclin A expression, known to be essential for cell cycle progression. Moreover, 
several studies showed that EZH2 is a transcriptional repressor of RUNX3 expression, a known 
tumor suppressor gene in several cancers, including CRC.110-112 RUNX3 is a member of the 
Runt-related (RUNX) family of genes with important roles in normal development and 
carcinogenesis. It has been shown that RUNX3 up-regulates p21, an important element in cell 
cycle control by inhibitin cyclin-dependent kinase113. Accordingly, not only EZH2 plays an 
important role in the progression of the cell cycle by increasing cyclin A, but also in the release 
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of p21, one important inhibitor of cyclin E. Similarly, EZH2 has been found to affect tumor cell 
proliferation through down-regulation of RUNX3 110. Moreover, RUNX3 is also a determinant 
for up-regulation of Bim, a proapoptotic protein, thus demonstrating a crucial role in the 
induction of apoptosis114. In addition, this EZH2 target gene negatively regulates Wnt signaling 
activity, which is overexpressed in colon cancer playing a crucial role in tumor initiation, 
through interaction with the b-catenin/T cell factor 4 (TCF4) transcription factor complex115. 
Because RUNX3 inactivation is primarily conducted by epigenetic mechanisms, its reactivation 
by specific inhibitors of EZH2 could represent a promise option for CRC treatment. 
 
SETDB1, a histone methyltransferase responsible for the trimethylation of lysine 9 of 
histone H3 which promotes the transcriptional repression of genes, exhibits a methyl-CpG-
binding domain (MBD) and functions in association with DNA methylation.116-118 Contrarily to 
EZH2, little information is available concerning SETDB1 expression in cancer cells.119, 120 
Remarkably, SETDB1 has been reported to promote H3K9 trimethylation patterns at the 
RASSF1A promoter116, a tumor suppressor gene frequently silenced in lung, bladder, prostate, 
gastric and breast cancers121, 122. Watanabe and collaborates demonstrated that inhibition of 
SETDB1 in non-small cell lung cancer cell lines resulted in cell cycle arrest123. In contrast to the 
tumor promoting role reported in previous studies, SETDB1 has been found to inhibit Wnt target 
genes in an animal model of CRC124, favoring a protective role of SETDB1 in this type of 
cancer. In our series, SETDB1 expression in CRC cells did not differ significantly from the 
expression in the adjacent morphologically normal mucosa, and it was not associated with 
prognostically relevant clinicopathological features of CRC. Interestingly, however, SETDB1 
expression was significantly higher in left-sided CRCs, suggesting a putative role of this histone 
modifier enzyme in the carcinogenesis of chromosomic instable CRCs, which predominate in the 
left colon.125 Levels of SETDB1 expression were not associated with H3K27me3 expression 
levels, suggesting that SETDB1 does not play the major role in H3K27 methylation in CRC. 
Moreover, SETDB1 expression was neither associated with overall survival rate of the CRC 
patients nor with survival rate amongst patients treated with the therapeutic agents previously 
described. However, high levels of SETDB1 expression were associated with decreased survival 
rate in stage I and II, treated with surgery alone, suggesting that whenever the expression of 
SETDB1 occurs, the surgical treatment may not be enough to prolong the patient’s survival. 
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SMYD3 is a histone methyltransferase that specifically binds to DNA sequences in the 
promoter region of target genes and methylates lysine 4 of histone H3 (H3K4), leading to gene 
activation.126 Upregulation of SMYD3 expression in cultured cells increased cell growth whereas 
dowregulation of SMYD3 expression had the opposite effect. Foreman and collaborates found 
that SMYD3 also methylates lysine 20 in histone H4 (H4K20), a well known repressive histone 
mark.127 Therefore, SMYD3 overexpression is thought to activate normally silent oncogenes and 
repress tumor suppressor genes, contributing to cancer initiation and progression.51 These 
observations disclose the complexity of the epigenetic regulation and the relevance of targeting 
SMYD3 expression in the appropriate pathway. Although microarray analysis showed 
upregulation of SMYD3 expression in several cancers, including CRC, hepatocellular carcinoma 
and breast carcinoma 126, 128, only a few direct target genes are known, including cell cycle 
regulators and oncogenes.126, 129-131 The canonical activation of the Wnt/β-catenin pathway is one 
of the most frequent signaling alterations in CRC and it has been demonstrated that WNT10B is a 
direct downstream gene activated by SMYD3.132 Since downregulation of SMYD3 expression in 
cancer cell lines significantly reduces cell growth, therapeutic blockage of this pathway could 
prove useful in CRC.126, 128 Finally, SMYD3 increases expression of MMP-9, one of the matrix 
metalloproteinase (MMP) proteins that play crucial functions in carcinogenesis and metastasis 
development by regulating cell migration and invasion.134 
In the present study, SMYD3 was expressed in all CRC cases and was not associated 
with any of the considered clinicopathological features. This result is consistent with previous 
studies and supports the hypothesis that this histone modifier enzyme may play a role in CRC 
initiation. Interestingly, in our cases the expression of SMYD3 was detected in the cell 
membrane and cytoplasm of CRC cells, with only residual nuclear expression. Hamamoto and 
collaborates had already shown that subcellular localization of SMYD3 changes according to the 
cell cycle, accumulating in the nucleus at S phase and G2-M and accumulating in the cytoplasm 
when cells are arrested at Go-G1.126 He and collaborates detected SMYD3 expression 
predominantly in the cytoplasm, but also in the nucleus, in hepatocellular carcinoma.135 As far as 
we know, this is the first observation of SMYD3 expression almost exclusively in the cell 
membrane and in the cytoplasm in a malignant neoplasm. The explanation for this finding may 
be related with the fact that histone modifying enzymes can also operate on non-histone proteins, 
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through acetylation and methylation in specific residues, although only a few examples of lysine 
methylation have been described. Curiously, almost all of this non-histone proteins reported, 
including transcription factors, are related with gene regulation.136 The p53 protein is an example 
of non-histone protein known to be regulated by lysine methylation. Both activation and 
inactivation of this protein can be achieved according to the specific lysine residue methylated. 
Interestingly, SMYD2 is a lysine methyltransferase able to methylate and silence p53. Although 
such activity has not been found for SMYD3,137 this enzyme depicts methyltransferase activity 
on nonhistone proteins, namely VEGFR1, a receptor tyrosine kinase, enhancing its kinase 
activity.138 Although VEGFR1 was thought to be expressed only in vascular endothelial cells, it 
is currently acknowledged that it may be expressed by a variety of tissues, including CRC.139, 140 
Additionally, it has been shown that increases in VEGFR1 expression are associated with 
enhanced migration and invasion of cancer cells.141, 142 Taken together, it is tempting to speculate 
based on our findings that increase expression of SMYD3 may enhance the invasiveness of CRC 
cells through the action of VEGFR1. 
 
Alongside with three histone methyltransferases, we also assessed the immunoexpression 
of a histone demethylase - LSD1. This enzyme directly demethylates lysine 4 in histone H3, a 
repressive mark, and, in prostate cancer cell lines, it interacts with androgen receptor and 
demethylates H3K9, activating androgen-dependent gene transcription 143, 144 Hence, depending 
on the cellular and environmental context, the same enzyme may produce opposite effects 
regarding gene regulation. Lim and collaborates showed that LSD1 expression was higher in 
estrogen receptor-negative breast cancers compared to normal breast tissues and estrogen 
receptor-positive breast cancers.145 Furthermore, Kahl and collaborates showed that high levels 
of LSD1 expression were associated with increased histological grade and relapse in prostate 
cancer patients.146 The precise mechanism of LSD1 in cancer initiation and progression is 
unknown, although a recent study has shown that LSD1 could promote G2-M phase transition 
and cell proliferation, probably mediated by cyclin A2.145, 147 Inhibition of LSD1 expression in 
human CRC cells (both in vitro and in animal models) resulted in decreased cell growth and re-
expression of several genes, including the Wnt signaling pathway antagonist family members.148, 
149 Dowregulation of LSD1 in breast cancer cell lines resulted in growth inhibition and increased 
expression of several genes, namely those involved in cell cycle regulation and cell migration, 
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such as p21 and E-cadherin.145, 150, 151 Therefore, inhibition of LSD1 expression may represent a 
new epigenetic target in oncology. 
In our study, CRC cells overexpressed LSD1, compared to morphologically normal 
colonic epithelial cells. On the other hand, LSD1 expression was significantly lower in more 
invasive tumors and at advanced stages, suggesting a double role for this histone modifier 
enzyme in CRC transformation and progression. Wang and collaborates showed that LSD1 is 
involved in dowregulation of TGFb-1 signaling pathway, which is important for epithelial-
mesenchymal transition and invasiveness.152 Our results support the hypothesis that CRC cases 
with low LSD1 expression may activate a more convenient program in order to invade and 
metastasize, although LSD1 expression was not associated with overall survival in our series of 
CRC patients. However, high levels of LSD1 expression were associated with better survival 
within the group of CRC patients treated with Folfiri (ρ=0.008), suggesting that LSD1 may 
constitute a predictive marker of therapeutic response in this subset of CRC patients. 
Nevertheless, these findings need to be confirmed in a larger CRC series. 
 
3. Expression of histone marks H3K9me3 and H3K27me3 in CRC 
The N-terminal tail of histone H3 can be methylated at multiple lysine (K) residues by 
histone methyltransferases. Methylation of lysine 9 in histone H3 (H3K9) is frequently 
associated with the epigenetic control of heterochromatin assembly and with gene silencing in 
cancer cells.153-156 Nevertheless, any given modification has the potential to activate or repress 
gene transcription under different conditions. Recently, the finding that H3K9me3 is enriched in 
the coding regions of active genes has challenged the dogma that H3K9me3 is always associated 
with downregulation of gene transcription.157 Probably, methylation at H3K9 within the coding 
regions has an activation effect in gene transcription whereas in the promoter regions it has the 
opposite effect.49 
In our series of CRC cases, the histone mark H3K9me3 was highly expressed in the 
tumor cells compared to normal epithelial cells of the adjacent apparently normal mucosa. 
Interestingly, expression of H3K9me3 in tumor cells was also significantly higher in CRCs 
displaying lymph node metastases, suggesting that the genes activated or repressed by H3K9me3 
might be involved in signaling pathways related with metastatic behavior. It should be 
emphasized, however, that the expression of this histone mark reflects the global level of histone 
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modifications in the tumor cells genome, and it does not necessarily indicate whether this 
modification is actually present in the coding region or in the promoter region. Consequently, we 
can only speculate on how H3K9me3 is affecting gene transcription (activation vs. repression). 
Several researchers, using epigenetic marks such as H3K9me3, have identified subgroups 
of patients with different prognosis and/or different responses to treatment. Seligson and 
collaborates reported that lower cellular levels of H3K9me2 were associated with poorer 
outcome in prostate and kidney cancers.75 Additionally, Manuyakorn and collaborates showed 
that low cellular levels of H3K9me2 were not only associated with poor survival in pancreatic 
adenocarcinomas but also in patients receiving adjuvant fluorouracil.82 Although in our study a 
lower survival rate in CRC cases with low H3K9me3 expression in tumor cells was observed, 
this difference did not reach statistical significance. However, high levels of H3K9me3 
expression were associated with better survival within the subset of patients treated with 5-
FU/Leucovorine and Folfiri. To the best of our knowledge, this is the first evidence of H3K9me3 
as an epigenetic biomarker for prediction of clinical outcome and response to therapy in CRC. 
 
The N-terminal tail of histone H3 can also be methylated at lysine 27 (H3K27), a feature 
that is frequently associated with gene silencing. Wei and collaborates reported that H3K27me3 
expression is lower in malignant tumors (namely breast, ovarian and pancreatic) compared to 
their normal counterparts.78 
In our study, H3K27me3 expression was higher in CRC cells compared to 
morphologically normal colonic epithelial cells. Once again, the observed immunoexpression 
reflects the global level of histone modifications in tumor cells, rather than indicating whether 
this modification is specifically occurring at the coding or the promoter region of genes. 
However, most, if not all published studies, associate this mark with gene transcription 
inactivation. Tzao and collaborates reported a positive relationship between tumor differentiation 
and high H3K27me3 expression in squamous cell carcinoma of the esophagus. Moreover, high 
levels of H3K27me3 expression were also seen more frequently in cases with lymph node 
involvement and advance stages of disease.81 Our findings are in line with those observations, as 
the expression of H3K27me3 was significantly higher in CRCs depicting lymph and venous 
vessel invasion. Furthermore, H3K27me3 expression was significantly higher in more invasive 
CRCs, as well as in those with lymph node metastases and at advanced disease stages. 
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Tzao and collaborates also demonstrated that high expression of H3K27me3 was 
independently associated with poor survival in patients with esophageal squamous cell 
carcinoma, especially at early stages.81 However, Wei and collaborates revealed that high 
H3K27m3expression was independently associated with better overall survival rate in breast, 
ovarian and pancreatic cancers.78 We found that high H3K27me3 expression in CRC cells was 
associated with worse outcome compared to cases with low expression of H3K27me3, although 
this difference is not statistically significant. Nevertheless, high levels of H3K27me3 expression 
were significantly associated with improved survival within a subset of patients treated with 5-
FU/Leucovorine, a finding that has not been reported before. Remarkably, high H3K9me3 and 
H3K27me3 expression levels were mutually associated, suggesting a cooperative role in gene 
transcription deregulation in CRC. Thus, global expression of histone marks, specifically 
H3K9me3 and H3K27me3 should be explored in larger series of patients to definitely assess 
their role as potential epigenetic biomarkers for prediction of response to therapeutics in CRC 
patients. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
CRC, as cancer in general, is a disease characterized by genetic and epigenetic 
modifications. Histone modifications, alongside with genetic alterations and DNA methylation, 
are important mechanisms of regulation of gene expression and synergistically contribute to 
neoplastic transformation and tumor progression. 
The conclusions of our study are as follow: 
1. In the selected CRC cases we observed that the presence of venous vessel invasion, 
positive surgical margins, regional lymph node metastases, distant metastases and 
tumor stage were associated with decreased survival rate of the patients. 
2. Considering the difference between the expression of histone modifying enzymes and 
histone marks in CRC cells and their expression in the cells of the normal mucosa: 
a. The histone methyltransferases EZH2 and SMYD3 and the histone 
demethylase LSD1 were overexpressed in CRC cells, suggesting a role for 
these enzymes in the neoplastic transformation of CRC. 
b. The expression of SMYD3 was observed mainly in the cell membrane and in 
the cytoplasm, in contrast with the nuclear expression observed in the 
remaining histone modifying enzymes. 
c. The expression of histone marks H3K9me3 and H3K27me3 were increased in 
CRC cells, suggesting that the putative role of the abovementioned histone 
modifying enzymes is mediated by the methylation of H3K9 and H3K27. 
3. Regarding the association between the expression of histone modifying enzymes and 
the expression of histone marks with the clinicopathological features of CRC cases, 
we observed: 
a. Higher EZH2 expression in more invasive CRCs and CRCs with regional 
lymph node metastases, suggesting that EZH2 may have a role in tumor 
growth and cell invasion. 
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b. Higher SETDB1 expression in left-sided CRCs, suggesting a putative role in 
the carcinogenesis of chromossomic instable CRCs. 
c. Lower LSD1 expression in more invasive CRCs and in CRCs at advanced 
stages of disease, suggesting that LSD1 may be associated with less 
aggressive CRCs. 
d. Higher H3K9me3 expression in CRCs with regional lymph node metastases, 
which appears to be associated to the putative role of EZH2 in the progression 
of CRC. 
e. Higher H3K27me3 expression in more invasive CRCs, CRCs with regional 
lymph node metastases and in CRCs at advanced stages of disease, as well as 
in CRCs with lymph and venous vessel invasion, which appears to be 
associated to the putative role of EZH2 in the progression of CRC. 
4. In this study we did not detected any differences in the survival rate of the patients 
with CRC considering the different expression of the studied histone modifying 
enzymes or histone marks. 
5. Regarding the therapeutic response, we observed: 
a. Higher survival rates of patients with CRCs treated only with surgery that 
disclosed lower SETDB1 expression, suggesting that whenever the expression 
of SETDB1 occurs, the surgical treatment may not be enough to prolong the 
patient’s survival. 
b. Higher survival rates of patients with CRC treated with Folfiri that disclosed 
high LSD1 and H3K9me3 expression in cancer cells, suggesting that LSD1 
expression and the histone mark H3K9me3 can predict the response to this 
treatment modality. 
c. Higher survival rates of patients with CRC treated with 5-FU/Leucovorine 
that disclosed high H3K9me3 and H3K27me3 expression in cancer cells, 
suggesting that these patterns of methylation can predict the response to this 
treatment modality. 
6. Additionally, we verified that the evaluation of histone modifying enzymes and 
histone marks using a low/high expression system reproduced the results obtained 
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with the H-score, constituting an easier system to evaluate the expression of the 
histone modifying enzymes and histone marks in the routine of a pathologist. 
 
Following the above mentioned conclusions, we propose new studies to highlight the role 
of histone modifying enzymes and histone marks in the neoplastic transformation and 
progression of CRC as well as their association with the therapeutic response: 
1. Study of the above mentioned histone modifying enzymes and histone marks in 
larger, independent series to validate our results. 
2. Identification of signaling pathways targeted by SETDB1 in order to explain its 
association with localized CRC prognosis. 
3. Identification of cytoplasmic molecular targets of SMYD3 to clarify its putative role 
in CRC carcinogenesis. 
4. Evaluation of the expression of the studied histone modifying enzymes and histone 
marks in CRC metastases to disclose their association with the response to treatment. 
5. Evaluation of the expression of additional histone modifying enzymes and histone 
modifications to identify new prognostic markers in CRC. 
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